Topics: Buy Penny Stocks Like Hedge Funds...; $TU would be somewhere between...; Jabil Q3 22 Earnings Conference... and many other

[Limex] Dear {NAME}, Some topics you might have missed. --------------------------------------------------------------- [Buy Penny Stocks Like Hedge Funds Do: A How-To Guide]( Have you ever wanted to buy penny stocks that top Wall Street hedge funds and prominent investors do? It’s not as mysterious as you might think. In … [Read more]( Penny Stocks [PennyStocks.com] --------------------------------------------------------------- [$TU would be somewhere between $20.38 and $21.48 by 16 June 2022.]( … [Read more]( Just In --------------------------------------------------------------- [Jabil Q3 22 Earnings Conference Call At 8:30 AM ET]( (RTTNews) - Jabil Inc. (JBL) will host a conference call at 8:30 AM ET on June 16, 2022, to discuss Q3 22 earnings results. To access the live … [Read more]( Just In --------------------------------------------------------------- [GBPUSD poised to continue the channel]( Bullish: We are currently @ 1.2188 after a channel wall bounce. We are looking for a continuation to the ATR target@ 1.2323 area and then the 0.618 … [Read more]( Scott Barkley --------------------------------------------------------------- [VOO, AMZN, TSLA, GOOGL: Large Inflows Detected at ETF]( Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard S&P … [Read more]( Just In --------------------------------------------------------------- [Stock Market Outlook for June 17, 2022]( Looking out for the cues that would suggest selling exhaustion in order to flip back to risk-on in the equity market.  Real Time Economic … [Read more]( Tech Talk Financial Network --------------------------------------------------------------- [Edwards Lifesciences (EW) Stock Moves -1.18%: What You Should Know]( Edwards Lifesciences (EW) closed the most recent trading day at $87.73, moving -1.18% from the previous trading session. This change was narrower than the S&P 500's daily loss of 3.25%. Meanwhile, the Dow lost 2.42%, and the Nasdaq, a tech-heavy index, lost 0.41%. Heading into today, shares of the medical device maker had lost 4.96% over the past month, lagging the Medical sector's loss of 1.96% and outpacing the S&P 500's loss of 5.62% in that time. Edwards Lifesciences will be looking to display strength as it nears its next earnings release. On that day, Edwards Lifesciences is projected to report earnings of $0.64 per share, which would represent no growth from the year-ago period. Meanwhile, our latest consensus estimate is calling for revenue of $1.4 billion, up 1.92% from the prior-year quarter. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.57 per share and revenue of $5.72 billion. These totals would mark changes of +15.77% and +9.29%, respectively, from last year. It is also important to note the recent changes to analyst estimates for Edwards Lifesciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.13% higher within the past month. Edwards Lifesciences currently has a Zacks Rank of #3 (Hold). In terms of valuation, Edwards Lifesciences is currently trading at a Forward P/E ratio of 34.6. This valuation marks a premium compared to its industry's average Forward P/E of 26.42. Meanwhile, EW's PEG ratio is currently 2.5. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 1.89 as of yesterday's close. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 188, which puts it in the bottom 26% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Special Report: The Top 5 IPOs for Your Portfolio Today, you have a chance to get in on the ground floor of one of the best investment opportunities of the year. As the world continues to benefit from an ever-evolving internet, a handful of innovative tech companies are on the brink of reaping immense rewards - and you can put yourself in a position to cash in. One is set to disrupt the online communication industry. Brilliantly designed for creating online communities, this stock is poised to explode when made public. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity. >>See Zacks’ Hottest IPOs Now Click to get this free report Edwards Lifesciences Corporation… … [Read more]( Just In --------------------------------------------------------------- [Regeneron (REGN) Stock Moves -0.79%: What You Should Know]( Regeneron (REGN) closed at $556.75 in the latest trading session, marking a -0.79% move from the prior day. This change was narrower than the S&P 500's daily loss of 3.25%. At the same time, the Dow lost 2.42%, and the tech-heavy Nasdaq lost 0.48%. Coming into today, shares of the biopharmaceutical company had lost 14.87% in the past month. In that same time, the Medical sector lost 1.96%, while the S&P 500 lost 5.62%. Regeneron will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $9.94, down 61.47% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $2.77 billion, down 46% from the year-ago period. REGN's full-year Zacks Consensus Estimates are calling for earnings of $42.38 per share and revenue of $11.57 billion. These results would represent year-over-year changes of -43.24% and -28.03%, respectively. Any recent changes to analyst estimates for Regeneron should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.91% higher within the past month. Regeneron is holding a Zacks Rank of #3 (Hold) right now. Valuation is also important, so investors should note that Regeneron has a Forward P/E ratio of 13.24 right now. Its industry sports an average Forward P/E of 20.16, so we one might conclude that Regeneron is trading at a discount comparatively. Also, we should mention that REGN has a PEG ratio of 1.66. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.07 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 105, putting it in the top 42% of all 250+ industries. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Special Report: The Top 5 IPOs for Your Portfolio Today, you have a chance to get in on the ground floor of one of the best investment opportunities of the year. As the world continues to benefit from an ever-evolving internet, a handful of innovative tech companies are on the brink of reaping immense rewards - and you can put yourself in a position to cash in. One is set to disrupt the online communication industry. Brilliantly designed for creating online communities, this stock is poised to explode when made public. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity. >>See Zacks’ Hottest IPOs Now Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on … [Read more]( Just In --------------------------------------------------------------- [$AMZN would be somewhere between $102.14 and $110.76 by 16 June 2022.]( … [Read more]( Just In --------------------------------------------------------------- [US STOCKS-Futures slump as recession fears loom]( For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Futures down: Dow 2%, S&P 2.5%, … [Read more]( Just In --------------------------------------------------------------- [Amazon and Walmart Are Capitalizing on This Incremental Revenue Stream]( Amazon (NASDAQ: AMZN) and Walmart (NYSE: WMT) are retail powerhouses that generate hundreds of billions in consumer sales every year. More recently, … [Read more]( Just In --------------------------------------------------------------- [The Dow Got Crushed -- Here Are 4 Stocks That Survived the Bloodbath]( Although the markets looked fine yesterday after the Federal Reserve raised its benchmark lending rate by three-quarters of a percentage point, it … [Read more]( Just In Follow us limex.me limex.me Warning: The links given in this email provide an automatic login to your account. For security purposes, do not share them with anyone. You received this letter because you created a Limex/WhoTrades/Try2BFunded/Score Priority/Just2Trade account. Do you want to unsubscribe from email notifications? [Edit your message settings](.